DRUG
Retatrutide
Administered SC
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Status
Active, not recruiting
Phase
Phase 3
Enrollment
250
Locations
31
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Interventions
Treatment arms and agents.
DRUG
Placebo
Administered SC
Timeline
From registration to results.
First posted
Nov 18, 2025
Study start
Nov 17, 2025
Primary completion
Jul 2027
Study completion
Jul 2027
Results posted
Not reported
Registry updated
Apr 17, 2026
Outcomes
What the study measures.
Primary outcomes
Percent Change from Baseline in Body Weight
Time frame · Baseline, Week 56
Secondary outcomes
Change from Baseline in Systolic Blood Pressure
Time frame · Baseline, Week 56
Change from Baseline in Waist Circumference
Time frame · Baseline, Week 56
Percent Change from Baseline in Non-High-Density Lipoprotein (HDL) Cholesterol
Time frame · Baseline, Week 56
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC)
Time frame · Baseline through Week 56
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Have a body mass index (BMI) of: * ≥30 kilogram per square meter (kg/m2) OR * ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kg (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening * acute myocardial infarction * cerebrovascular accident (stroke) * hospitalization for unstable angina, or * hospitalization due to congestive heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening
Study locations
31 registered sites.
United Kingdom · United States. Showing up to 24 locations stored in the fast local snapshot.
Artemis Institute for Clinical Research
Riverside, California, United States
JEM Research Institute
Atlantis, Florida, United States
Headlands Research Orlando
Orlando, Florida, United States
Care Access - Tamarac
Tamarac, Florida, United States
Care Access - Arlington Heights
Arlington Heights, Illinois, United States
L-MARC Research Center
Louisville, Kentucky, United States
IMA Clinical Research Monroe - Armand
Monroe, Louisiana, United States
Pharmasite Research, Inc.
Baltimore, Maryland, United States
Clinical Research Professionals
Chesterfield, Missouri, United States
Clinvest Headlands Llc
Springfield, Missouri, United States
IMA Clinical Research Warren
Warren Township, New Jersey, United States
IMA Clinical Research Manhattan
New York, New York, United States
Trial Management Associates - Wilmington - Floral Parkway
Wilmington, North Carolina, United States
Cedar Health Research
Dallas, Texas, United States
Headlands Research-El Paso
El Paso, Texas, United States
Cedar Health Research - Euless
Euless, Texas, United States
Cedar Health Research - Fort Worth
Fort Worth, Texas, United States
Care Access - Houston
Houston, Texas, United States
IMA Clinical Research San Antonio
San Antonio, Texas, United States
FutureMeds - Birmingham
Birmingham, United Kingdom
Layton Medical Centre
Blackpool, United Kingdom
Bradford on Avon Health Centre
Bradford-on-Avon, United Kingdom
FutureMeds - Liverpool
Bromborough, United Kingdom
Cheadle Community Hospital
Cheadle, United Kingdom
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Retatrutide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly · Obesity · Cardiovascular Diseases
Phase 3
Completed
1,946
2026-07
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly · Type 2 Diabetes · Obesity
Phase 3
Completed
1,152
2026-07
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly · Obesity · Overweight
Phase 3
Active, not recruiting
586
2026-07
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly · Type 2 Diabetes
Phase 3
Active, not recruiting
320
2026-07
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly · Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Phase 3
Active, not recruiting
10,000
2026-07
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly · Obesity
Phase 3
Active, not recruiting
800
2026-07
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly · Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase 3
Recruiting
4,500
2026-07
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly · Diabetes Mellitus · Insulin Sensitivity
Phase 1
Active, not recruiting
95
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.